236 related articles for article (PubMed ID: 31786434)
1. Model-based cost-effectiveness estimates of testing strategies for diagnosing hepatitis C virus infection in people who use injecting drugs in Senegal.
Duchesne L; Hejblum G; Toure Kane NC; Njouom R; Toni TD; Moh R; Sylla B; Rouveau N; Attia A; Lacombe K
Int J Drug Policy; 2020 Jan; 75():102613. PubMed ID: 31786434
[TBL] [Abstract][Full Text] [Related]
2. Model-based cost-effectiveness estimates of testing strategies for diagnosing hepatitis C virus infection in Central and Western Africa.
Duchesne L; Hejblum G; Njouom R; Touré Kane C; Toni TD; Moh R; Sylla B; Rouveau N; Attia A; Lacombe K
PLoS One; 2020; 15(8):e0238035. PubMed ID: 32833976
[TBL] [Abstract][Full Text] [Related]
3. Increasing hepatitis C virus screening in people who inject drugs in Switzerland using rapid antibody saliva and dried blood spot testing: A cost-effectiveness analysis.
Girardin F; Hearmon N; Negro F; Eddowes L; Bruggmann P; Castro E
J Viral Hepat; 2019 Feb; 26(2):236-245. PubMed ID: 30338887
[TBL] [Abstract][Full Text] [Related]
4. Utility of a one-step screening and diagnosis strategy for viremic HCV infection among people who inject drugs in Catalonia.
Saludes V; Antuori A; Folch C; González N; Ibáñez N; Majó X; Colom J; Matas L; Casabona J; Martró E;
Int J Drug Policy; 2019 Dec; 74():236-245. PubMed ID: 31706159
[TBL] [Abstract][Full Text] [Related]
5. The testing of people with any risk factor for hepatitis C in community pharmacies is cost-effective.
Buchanan R; Cooper K; Grellier L; Khakoo SI; Parkes J
J Viral Hepat; 2020 Jan; 27(1):36-44. PubMed ID: 31520434
[TBL] [Abstract][Full Text] [Related]
6. Upscaling prevention, testing and treatment to control hepatitis C as a public health threat in Dar es Salaam, Tanzania: A cost-effectiveness model.
Scott N; Mohamed Z; Rwegasha J; Mbwambo J; Lemoine M; Hellard M
Int J Drug Policy; 2021 Feb; 88():102634. PubMed ID: 31882272
[TBL] [Abstract][Full Text] [Related]
7. Assessing the potential cost-effectiveness of centralised versus point-of-care testing for hepatitis C virus in Pakistan: a model-based comparison.
Babigumira JB; Karichu JK; Clark S; Cheng MM; Garrison LP; Maniecki MB; Hamid SS
BMJ Open; 2023 May; 13(5):e066770. PubMed ID: 37142306
[TBL] [Abstract][Full Text] [Related]
8. Acceptability and preferences of point-of-care finger-stick whole-blood and venepuncture hepatitis C virus testing among people who inject drugs in Australia.
Bajis S; Maher L; Treloar C; Hajarizadeh B; Lamoury FMJ; Mowat Y; Schulz M; Marshall AD; Cunningham EB; Cock V; Ezard N; Gorton C; Hayllar J; Smith J; Whelan M; Martinello M; Applegate TL; Dore GJ; Grebely J;
Int J Drug Policy; 2018 Nov; 61():23-30. PubMed ID: 30388566
[TBL] [Abstract][Full Text] [Related]
9. The cost-effectiveness of testing for hepatitis C in former injecting drug users.
Castelnuovo E; Thompson-Coon J; Pitt M; Cramp M; Siebert U; Price A; Stein K
Health Technol Assess; 2006 Sep; 10(32):iii-iv, ix-xii, 1-93. PubMed ID: 16948891
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of the Xpert HCV VL Fingerstick point-of-care assay and dried blood spot HCV-RNA testing as simplified diagnostic strategies among people who inject drugs in Catalonia, Spain.
Saludes V; Antuori A; Lazarus JV; Folch C; González-Gómez S; González N; Ibáñez N; Colom J; Matas L; Casabona J; Martró E
Int J Drug Policy; 2020 Jun; 80():102734. PubMed ID: 32470849
[TBL] [Abstract][Full Text] [Related]
11. Hepatitis C Virus Screening of High-Risk Patients in a Canadian Emergency Department.
Ragan K; Pandya A; Holotnak T; Koger K; Collins N; Swain MG
Can J Gastroenterol Hepatol; 2020; 2020():5258289. PubMed ID: 32211349
[TBL] [Abstract][Full Text] [Related]
12. Economic evaluation of HCV testing approaches in low and middle income countries.
Morgan JR; Servidone M; Easterbrook P; Linas BP
BMC Infect Dis; 2017 Nov; 17(Suppl 1):697. PubMed ID: 29143681
[TBL] [Abstract][Full Text] [Related]
13. Effectiveness and cost-effectiveness of nationwide campaigns for awareness and case finding of hepatitis C targeted at people who inject drugs and the general population in the Netherlands.
Helsper CW; Janssen MP; van Essen GA; Croes EA; van der Veen C; de Wit AG; de Wit NJ
Int J Drug Policy; 2017 Sep; 47():117-125. PubMed ID: 28826994
[TBL] [Abstract][Full Text] [Related]
14. Combining rapid diagnostic tests and dried blood spot assays for point-of-care testing of human immunodeficiency virus, hepatitis B and hepatitis C infections in Burkina Faso, West Africa.
Kania D; Bekalé AM; Nagot N; Mondain AM; Ottomani L; Meda N; Traoré M; Ouédraogo JB; Ducos J; Van de Perre P; Tuaillon E
Clin Microbiol Infect; 2013 Dec; 19(12):E533-41. PubMed ID: 23902574
[TBL] [Abstract][Full Text] [Related]
15. Identifying cost-effective screening algorithms for active hepatitis C virus infections in a high prevalence setting.
Jülicher P; Galli C
J Med Econ; 2018 Jan; 21(1):1-10. PubMed ID: 28881157
[TBL] [Abstract][Full Text] [Related]
16. Assessing Molecular Point-of-Care Testing and Dried Blood Spot for Hepatitis C Virus Screening in People Who Inject Drugs.
Chevaliez S; Wlassow M; Volant J; Roudot-Thoraval F; Bachelard A; Poiteau L; Trabut JB; Hézode C; Bourdel A; Dominguez S
Open Forum Infect Dis; 2020 Jun; 7(6):ofaa196. PubMed ID: 32617372
[TBL] [Abstract][Full Text] [Related]
17. Cost-effectiveness of the HepCATT intervention in specialist drug clinics to improve case-finding and engagement with HCV treatment for people who inject drugs in England.
Ward Z; Reynolds R; Campbell L; Martin NK; Harrison G; Irving W; Hickman M; Vickerman P
Addiction; 2020 Aug; 115(8):1509-1521. PubMed ID: 31984606
[TBL] [Abstract][Full Text] [Related]
18. Reaching hepatitis C virus elimination targets requires health system interventions to enhance the care cascade.
Scott N; Doyle JS; Wilson DP; Wade A; Howell J; Pedrana A; Thompson A; Hellard ME
Int J Drug Policy; 2017 Sep; 47():107-116. PubMed ID: 28797497
[TBL] [Abstract][Full Text] [Related]
19. Detection of active hepatitis C in a single visit and linkage to care among marginalized people using a mobile unit in Madrid, Spain.
Ryan P; Valencia J; Cuevas G; Torres-Macho J; Troya J; Pueyo Á; José Muñoz-Gómez M; Muñoz-Rivas N; Vázquez-Morón S; Martinez I; Lazarus JV; Resino S
Int J Drug Policy; 2021 Oct; 96():103424. PubMed ID: 34429222
[TBL] [Abstract][Full Text] [Related]
20. Effectiveness and cost-effectiveness of interventions targeting harm reduction and chronic hepatitis C cascade of care in people who inject drugs: The case of France.
Cousien A; Tran VC; Deuffic-Burban S; Jauffret-Roustide M; Mabileau G; Dhersin JS; Yazdanpanah Y
J Viral Hepat; 2018 Oct; 25(10):1197-1207. PubMed ID: 29660211
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
